Citius pharmaceuticals to host investor call to discuss topline results of phase 3 trial of mino-lok antibiotic lock solution

Management call scheduled for monday, june 3, 2024 at 8:30 am et cranford, n.j. , may 29, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on monday, june 3, 2024 at 8:30 am et to discuss the topline results of its phase 3 trial of mino-lok antibiotic lock solution.
CTXR Ratings Summary
CTXR Quant Ranking